Evidence map›Paper›PMID 38932463›Full record

ArticleAging cell2024

Pathogenic tau induces an adaptive elevation in mRNA translation rate at early stages of disease.

Gabrielle Zuniga, Sakie Katsumura, Jasmine De Mange, Paulino Ramirez, Farzaneh Atrian, Masahiro Morita, Bess Frost

Abstract read
In one paragraph

Article in Aging cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. A murine model of amyloid-enhanced tauopathy: Comparison of wild-type and P301L-tau.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Riboregulation: a non-canonical tau function.Molecular neurodegeneration · 2026
    Review
  4. Article
  5. Article
  6. Long-read sequencing reveals genomic and epigenomic variation in the dark genome of human Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gabrielle ZunigaBarshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.
Sakie KatsumuraBarshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.
Jasmine De MangeBarshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.
Paulino RamirezBarshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.
Farzaneh AtrianBarshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.
Masahiro MoritaBarshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.
Bess FrostBarshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.ORCID 0000-0002-1212-8138

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Resource Component: Acquisition, maintenance and distribution of Drosophila stocksP40OD018537 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Annette L. Parks · 2014 to 2026
$13.5M
TRAINING GRANT ON THE BIOLOGY OF AGINGT32AG021890 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Erzsebet Kokovay, JAMES FLOYD NELSON · 2003 to 2026
$11.4M
Mechanisms of tau- and aging-induced neurological dysfunction: Focus on the nucleusR01AG057896 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FROST, BESS · 2019 to 2023
$2.8M
NRSA Training Core (TL1)TL1TR002647 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHUN, YONG-HEE PATRICIA, FREI, CHRISTOPHER R. · 2018 to 2022
$1.8M
Integrated Graduate Training Program in Neuroscience, UTHSCSAT32NS082145 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI David A Morilak · 2013 to 2026
$1.5M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM113896 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CAVAZOS, JOSE E · 2018 to 2022
$1.1M
Illumina NovaSeq 6000 Sequencing SystemS10OD030311 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2021 to 2021
$600k
NCATS NIH HHS TL1 TR002647NCI NIH HHS P30 CA054174NIA NIH HHS R01 AG057896NIA NIH HHS T32 AG021890NIGMS NIH HHS T32 GM113896NIH HHS P40 OD018537NIH HHS S10 OD030311NINDS NIH HHS T32 NS082145
6 · The paper itself

Abstract

Alterations in the rate and accuracy of messenger RNA (mRNA) translation are associated with aging and several neurodegenerative disorders, including Alzheimer's disease and related tauopathies. We previously reported that error-containing RNA that are normally cleared via nonsense-mediated mRNA decay (NMD), a key RNA surveillance mechanism, are translated in the adult brain of a Drosophila model of tauopathy. In the current study, we find that newly-synthesized peptides and translation machinery accumulate within nuclear envelope invaginations that occur as a consequence of tau pathology, and that the rate of mRNA translation is globally elevated in early stages of disease in adult brains of Drosophila models of tauopathy. Polysome profiling from adult heads of tau transgenic Drosophila reveals the preferential translation of specific mRNA that have been previously linked to neurodegeneration. Unexpectedly, we find that panneuronal elevation of NMD further elevates the global translation rate in tau transgenic Drosophila, as does treatment with rapamycin. As NMD activation and rapamycin both suppress tau-induced neurodegeneration, their shared effect on translation suggests that elevated rates of mRNA translation are an early adaptive mechanism to limit neurodegeneration. Our work provides compelling evidence that tau-induced deficits in NMD reshape the tau translatome by increasing translation of RNA that are normally repressed in healthy cells.

Indexed as

Protein BiosynthesisRNA, Messengertau ProteinsAnimalsAnimals, Genetically ModifiedDisease Models, AnimalDrosophilaDrosophila melanogasterHumansTauopathiesRNA, Messengertau ProteinsAlzheimer's diseaseDrosophilaneurodegenerationnonsense‐mediated mRNA decaynucleusprotein translationtauopathy

Identifiers

PMID38932463
PMCPMC11464109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.